Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Voxtalisib

Generic Name: Voxtalisib

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₄N_₆O

CAS Number: 934493-76-2

Unique Ingredient Identifier: CVL1685GPH

Overview

Voxtalisib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Breast Cancer, among others.

Background

Voxtalisib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Breast Cancer, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

Phase 2

Completed

Posted: 2013/09/06

Sponsor:EMD Serono

ID:NCT01936363

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Posted: 2012/05/10

Sponsor:Sanofi

ID:NCT01596270

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Phase 1

Completed

Posted: 2012/04/27

Sponsor:Sanofi

ID:NCT01587040

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 1

Completed

Posted: 2011/08/05

Sponsor:Sanofi

ID:NCT01410513

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Phase 2

Completed

Posted: 2011/07/27

Sponsor:Sanofi

ID:NCT01403636

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy